Biotechnology - sofosbuvir

Filter

Current filters:

sofosbuvir

Popular Filters

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan

16-06-2014

US anti-virals major Gilead Sciences has released strong top-line results from a Phase III clinical trial…

Anti-viralsBiotechnologyGilead SciencesJapanledipasvirRegulationResearchsofosbuvirSovaldi

Impressive data for once-daily sofosbuvir and ledipasvir treatment of HCV genotype 1

12-04-2014

Strong results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvirSovaldi

FDA priority review for Gilead’s ledipasvir/sofosbuvir fixed-dose combo for hepatitis C

FDA priority review for Gilead’s ledipasvir/sofosbuvir fixed-dose combo for hepatitis C

08-04-2014

US anti-virals major Gilead Sciences says that the US Food and Drug Administration has granted priority…

Anti-viralsBiotechnologyGilead SciencesledipasvirNorth AmericaRegulationsofosbuvirUSA

Idenix Pharma files law suits against Gilead in Europe over sofosbuvir

Idenix Pharma files law suits against Gilead in Europe over sofosbuvir

14-03-2014

US drugmaker Idenix Pharmaceuticals says it has filed patent infringement law suits against biotech firm…

Anti-viralsBiotechnologyGilead SciencesIdenix PharmaceuticalsLegalNorthern EuropePatentssofosbuvirSovaldi

Gilead files for US approval of ledipasvir/sofosbuvir combination for hepatitis C

Gilead files for US approval of ledipasvir/sofosbuvir combination for hepatitis C

11-02-2014

US biotech major Gilead Sciences has submitted a New Drug Application (NDA) to the US Food and Drug Administration…

Antibiotics and Infectious diseasesBiotechnologyGilead SciencesledipasvirRegulationsofosbuvirUSA

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries

07-02-2014

US biotech Gilead Sciences has indicated it would charge $2,000 per 24 week treatment course for the…

Anti-viralsBiotechnologyGilead SciencesGlobalIndiaPricingsofosbuvirSovaldi

Gilead’s Sovaldi approved in Canada for Genotypes 1, 2, 3 or 4 HCV

Gilead’s Sovaldi approved in Canada for Genotypes 1, 2, 3 or 4 HCV

16-12-2013

US antiviral biotech specialist Gilead Sciences says that Health Canada has issued a Notice of Compliance…

Anti-viralsBiotechnologyCanadaGilead SciencesNorth AmericaRegulationsofosbuvirSovaldi

US FDA approval for Gilead's hepatitis C drug Sovaldi

US FDA approval for Gilead's hepatitis C drug Sovaldi

08-12-2013

US antiviral biotech specialist Gilead Sciences says that the Food and Drug Administration has approved…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPricingRegulationsofosbuvirSovaldi

I-MAK challenges Gilead sofosbuvir patent in India

I-MAK challenges Gilead sofosbuvir patent in India

25-11-2013

USA-based advocacy group the Initiative for Medicines, Access & Knowledge last week filed a challenge…

Anti-viralsAsia-PacificBiotechnologyGilead SciencesPatentssofosbuvirSovaldi

Unanimous yes vote from FDA advisory panel for Gilead’s sofosbuvir in hep C

Unanimous yes vote from FDA advisory panel for Gilead’s sofosbuvir in hep C

27-10-2013

Following swiftly on a similar decision for Janssen’s hepatitis C drug simeprevir, the US Food and…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaRegulationsofosbuvir

Gilead's 1st-qtr profits rocket 63% on 11% revenue rise; moves forward with hep C program

03-05-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) has reported that revenues for the first quarter of 2013…

Anti-viralsBiotechnologyFinancialGilead SciencesledipasvirResearchsofosbuvir

Enrollment in Gilead's ION-1 study continues following planned DSMB review

26-03-2013

US HIV/AIDS and antiviral drugs specialist Gilead Sciences (Nasdaq: GILD) has provided a positive update…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvir

Gilead rises as sofosbuvir meets endpoints in Ph III hepatitis C study

20-02-2013

US AID/HIV drug giant Gilead Sciences (Nasdaq: GILD) saw its shares rise 2.5% to $42.60 in morning trading…

Anti-viralsBiotechnologyGilead SciencesResearchsofosbuvir

Positive results from two Ph III Studies of Gilead's sofosbuvir for hepatitis C

05-02-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) has revealed positive top-line results from two Phase…

Anti-viralsBiotechnologyGilead SciencesResearchsofosbuvir

Gilead Sciences updates on hepatitis C development programs

07-01-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) presented several updates regarding its late-stage pipeline…

Anti-viralsBiotechnologyGilead SciencesGS-5885Researchsofosbuvir

Back to top